

## Instructions For Healthcare Professionals: Prescribing Naloxone

Naloxone is the antidote for an opioid overdose. It has been used for decades to reverse respiratory depression associated with toxic exposure to opioids. Naloxone is not a controlled substance and can be prescribed by anyone with a medical license. Take-home naloxone can be prescribed to patients at risk of an opioid overdose. Some reasons for prescribing naloxone are:

- + Receiving emergency medical care involving opioid intoxication or overdose
- + Suspected history of substance abuse or nonmedical opioid use
- + Starting methadone or buprenorphine for addiction
- + Higher-dose (>50 mg morphine equivalent/day) opioid prescription
  - + Receiving any opioid prescription for pain plus:
  - + Rotated from one opioid to another because of possible incomplete cross-tolerance
  - + Smoking, COPD, emphysema, asthma, sleep apnea, respiratory infection, other respiratory illness
  - + Renal dysfunction, hepatic disease, cardiac illness, HIV/AIDS
  - + Known or suspected concurrent alcohol use
  - + Concurrent benzodiazepine or other sedative prescription
  - + Concurrent antidepressant prescription
- + Patients who may have difficulty accessing emergency medical services (distance, remoteness)
- + Voluntary request from patient or caregiver

Two naloxone formulations are available. Intra-muscular injection is cheaper but may be less attractive because it involves using a needle syringe. (IM syringes aren't widely used to inject controlled substances.) Intra-nasal (IN) spray is of comparable effectiveness but may be more difficult to obtain at a pharmacy. Check with pharmacist to see whether IM or IN is more feasible.

## Billing for Clinical Encounter to Prescribe Naloxone

Most private health insurance, Medicare, and Medicaid cover naloxone, but it varies by state.

### Billing Codes

**Commercial Insurance:** CPT 99408 (15 to 30 mins.)

**Medicare:** G0396 (15 to 30 mins.) **Medicaid:** H0050 (per 15 mins.)

## Screening, Brief Intervention and Referral to Treatment (SBIRT)

SBIRT can be used to bill time for counseling a patient. Complete the DAST-10 and counsel patient on how to recognize overdose and how to administer naloxone, using the following sheets. Refer to drug treatment program if appropriate.

Drug Abuse Screening Test-DAST-10		
These Questions Refer to the Past 12 Months	Yes	No
1. Have you used drugs other than those required for medical reasons?	<input type="checkbox"/>	<input type="checkbox"/>
2. Do you abuse more than one drug at a time?	<input type="checkbox"/>	<input type="checkbox"/>
3. Are you unable to stop using drugs when you want to?	<input type="checkbox"/>	<input type="checkbox"/>
4. Have you ever had blackouts or flashbacks as a result of drug use?	<input type="checkbox"/>	<input type="checkbox"/>
5. Do you ever feel bad or guilty about your drug use?	<input type="checkbox"/>	<input type="checkbox"/>
6. Does your spouse (or parents) ever complain about your involvement with drugs?	<input type="checkbox"/>	<input type="checkbox"/>
7. Have you neglected your family because of your use of drugs?	<input type="checkbox"/>	<input type="checkbox"/>
8. Have you engaged in illegal activities in order to obtain drugs?	<input type="checkbox"/>	<input type="checkbox"/>
9. Have you ever experienced withdrawal symptoms (felt sick) when you stopped	<input type="checkbox"/>	<input type="checkbox"/>
10. Have you had medical problems as a result of your drug use (e.g., memory loss, hepatitis, convulsions, bleeding)?	<input type="checkbox"/>	<input type="checkbox"/>

Guidelines for Interpretation of DAST-10		
Score	Degree of Problems Related to Drug Abuse	Suggested Action
0	No problems reported	Encouragement and education
1-2	Low level	Risky behavior - feedback and advice
3-5	Moderate level	Harmful behavior - feedback and counseling; possible referral k>r specialized assessment
6-8	Substantial level	Intensive assessment and referral

**Interpretation**  
**(Each "Yes" response = 1)**

*Skinner HA. The Drug Abuse Screening Test. Addictive Behavior. 1982;7(4):363-371*